After a painfully slow 2016, FDA's racking up drug approvals lickety-split

Fierce Pharma ------ Halfway into 2017, the FDA has beaten last year's drug-approvals tally with a crop featuring controversy, sales firepower and one very high price. Friday’s approval for the Portola anticoagulant Bevyxxa pushed the count for this year to 23, surpassing 2016’s new drug haul of 22, according to agency stats. The latest green light comes after the U.S. drug regulator signed off on more drugs in the first three months of the year—12—than during any other first quarter in recent years. So far, this year’s round of new drugs has triggered one pricing controversy and delivered two meds with some serious sales firepower. And among those 23, one has joined the ranks of the world’s most expensive treatments. To get more in depth information click on the picture below to read the article.